| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/ACS.BIOCONJCHEM.7B00697 |
| P8608 | Fatcat ID | release_c3us2hekyjadpapdagnv6nrnka |
| P932 | PMC publication ID | 6407425 |
| P698 | PubMed publication ID | 29350913 |
| P50 | author | John T Wilson | Q90281321 |
| Christian R Palmer | Q94270445 | ||
| P2093 | author name string | Anna M Pyle | |
| Olga Fedorova | |||
| Max E Jacobson | |||
| P2860 | cites work | Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus | Q24310706 |
| The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment | Q26796305 | ||
| PAMPs and DAMPs: signal 0s that spur autophagy and immunity | Q27004190 | ||
| Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity | Q27335125 | ||
| Defining the functional determinants for RNA surveillance by RIG-I | Q27679249 | ||
| Pathogen recognition and innate immunity | Q27861084 | ||
| Local innate immune responses in the vaccine adjuvant-injected muscle | Q28079872 | ||
| RIG-I in RNA virus recognition | Q28081618 | ||
| 5'-Triphosphate RNA is the ligand for RIG-I | Q28131726 | ||
| Viral evasion of intracellular DNA and RNA sensing | Q28392078 | ||
| Toll-like receptor control of the adaptive immune responses | Q29547305 | ||
| Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple | Q29615232 | ||
| Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment | Q30415355 | ||
| Structure-based programming of lymph-node targeting in molecular vaccines | Q33800766 | ||
| Unpaired 5' ppp-nucleotides, as found in arenavirus double-stranded RNA panhandles, are not recognized by RIG-I | Q33897708 | ||
| Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants | Q34120040 | ||
| In situ microscopy analysis reveals local innate immune response developed around Brucella infected cells in resistant and susceptible mice | Q34220948 | ||
| The role of glutathione in cancer. | Q34351043 | ||
| Human models of innate immunity: local and systemic inflammatory responses | Q34468581 | ||
| RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells | Q34486464 | ||
| The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. | Q35018021 | ||
| In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles | Q35229225 | ||
| Tunable degradation of maleimide-thiol adducts in reducing environments | Q35562329 | ||
| Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity | Q35634752 | ||
| A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. | Q36136253 | ||
| Modulation of Innate Immune Responses via Covalently Linked TLR Agonists | Q36333881 | ||
| Therapeutic potential of Toll-like receptor 9 activation | Q36501229 | ||
| Anti-angiogenic efficacy of 5'-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs | Q36557403 | ||
| Glutathione levels in human tumors | Q36717233 | ||
| siRNA conjugate delivery systems | Q37340480 | ||
| Designer vaccine nanodiscs for personalized cancer immunotherapy | Q37730767 | ||
| Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. | Q37775972 | ||
| Stimulus-responsive nanopreparations for tumor targeting | Q38032480 | ||
| Newly described pattern recognition receptors team up against intracellular pathogens | Q38120958 | ||
| Turning tumors into vaccines: co-opting the innate immune system | Q38124435 | ||
| Master sensors of pathogenic RNA - RIG-I like receptors | Q38125018 | ||
| Delivery materials for siRNA therapeutics | Q38154803 | ||
| Directing the immune system with chemical compounds | Q38201155 | ||
| Potential therapeutic targets in the process of nucleic acid recognition: opportunities and challenges | Q38283870 | ||
| Type I interferons in anticancer immunity | Q38509280 | ||
| Induction of necroptotic cell death by viral activation of the RIG-I or STING pathway | Q38722676 | ||
| Antitumour actions of interferons: implications for cancer therapy | Q38748641 | ||
| Triggering Intracellular Receptors for Vaccine Adjuvantation. | Q38913112 | ||
| TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles | Q39270978 | ||
| Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses. | Q39432584 | ||
| Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. | Q39822750 | ||
| Infection-mimicking materials to program dendritic cells in situ | Q39896570 | ||
| 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma | Q39922356 | ||
| First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. | Q40041145 | ||
| In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity | Q40937108 | ||
| Light Guided In-vivo Activation of Innate Immune Cells with Photocaged TLR 2/6 Agonist. | Q41388766 | ||
| Roles for Innate Immunity in Combination Immunotherapies | Q41996352 | ||
| Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer | Q44133324 | ||
| Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response | Q44857951 | ||
| Topical application of imiquimod and associated fever in children | Q45207660 | ||
| Complexation of lipofectamine and cholesterol-modified DNA sequences studied by single-molecule fluorescence techniques | Q46933860 | ||
| Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide | Q47592083 | ||
| Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity. | Q53444950 | ||
| Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates | Q56864501 | ||
| Polyelectrolyte Multilayers Assembled Entirely from Immune Signals on Gold Nanoparticle Templates Promote Antigen-Specific T Cell Response | Q85278186 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 742-747 | |
| P577 | publication date | 2018-01-19 | |
| P1433 | published in | Bioconjugate Chemistry | Q2343023 |
| P1476 | title | Environmentally Triggerable Retinoic Acid-Inducible Gene I Agonists Using Synthetic Polymer Overhangs | |
| P478 | volume | 29 |
| Q57480337 | Biomaterials for vaccine-based cancer immunotherapy |
| Q55508841 | Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. |
| Q64254798 | Knockdown of IGF-1R Triggers Viral RNA Sensor MDA5- and RIG-I-Mediated Mitochondrial Apoptosis in Colonic Cancer Cells |
Search more.